SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following its recent strategic partnership with C Speed LLC, which is positioned to deliver AI-enabled border security solutions, sparking community speculation about imminent large government contracts. Concurrently, investor discussions are highly focused on an upcoming proxy vote to increase authorized shares, with many expressing a desire for significant contract announcements to materialize before approving further potential dilution.

BitcoinII (BC2) is a proof-of-work, peer-to-peer digital currency that mirrors Bitcoin’s original monetary and consensus rules—21M max supply, ~10-minute blocks, halving every four years, and difficulty retargets every 2016 blocks—launched on a clean genesis with no premine and no ICO. The goal is simple: provide a familiar, dependable payments network focused on money, not data storage. BC2 supports SegWit and Taproot and is intentionally compatible with common Bitcoin tooling so miners, users, and exchanges can run it with minimal friction. It is positioned as a “sister chain,” not a replacement or competitor: another network using the same proven design so people can transact easily, run nodes on modest hardware, and participate from day one.

BitcoinII

BC2 CRYPTO (BitcoinII) is trending, driven by an anticipated exchange listing and strong community sentiment positioning it as a 'second chance' for early Bitcoin adopters. Enthusiasts are highlighting its identical design with a new genesis block and zero pre-mine, advocating it as an opportunity for a broader investor base and a return to original crypto principles.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO continues to trend with its highly engaged community constantly expressing "FFFFFUUUUUUUUUUUU" and "MUCH HIGHER" as key talking points, showcasing extreme bullish sentiment. The project is actively building on its OG meme status and Rage Comics lore, aiming to onboard millions of users and achieve a multi-billion dollar market value, with many believing it's a "true gem" positioned to outperform other established meme tokens.

PulteGroup, Inc. engages in the homebuilding business. The firm is also involved in mortgage banking and title and insurance brokerage operations. It operates through the Homebuilding and Financial services business segments. The Homebuilding segment includes operations from Connecticut, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Virginia, Georgia, North Carolina, South Carolina, Tennessee, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota, Missouri, Ohio, Texas, Arizona, California, Nevada, New Mexico, and Washington. The Financial Services segment is composed of mortgage banking and title operations. The company was founded by William J. Pulte in 1950 and is headquartered in Atlanta, GA.

PulteGroup Inc

PulteGroup is actively discussed following strong earnings reports that repeatedly show robust margins and increased orders, largely offsetting broader housing market concerns. The community debates whether this momentum can continue amid fluctuating mortgage rates and affordability challenges, despite management's optimistic outlook on a structural housing shortage. While some see homebuilders benefiting from potential rate adjustments, others remain cautious about sector valuations and increasing inventory.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus (PMV) is trending due to its highly engaged and 'infected' meme community, which consistently promotes its 'pure meme culture' across the Solana ecosystem, frequently interacting with other popular tokens like CAW and WEEDCOIN. The community is actively discussing its 'Viral Agenda' and long-term plans extending to 2026 and beyond, expressing strong bullish conviction for this meme asset.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending due to an active governance proposal aimed at activating its fee switch and implementing a substantial token burn mechanism. The community is engaged in discussions, anticipating this strategic shift will enhance token value by redirecting protocol fees to holders and potentially making UNI deflationary. This move is widely viewed as critical for aligning incentives and reinforcing Uniswap's prominent role within decentralized finance.

USELESS

USELESS CRYPTO is trending due to recent major exchange listings and new cross-chain transferability, significantly enhancing its market reach. The community exhibits strong bullish sentiment, highlighting substantial whale accumulation and anticipating significant upside, often embracing the token's ironically 'useless' nature as a key differentiator. This Solana meme coin is showing notable relative strength amidst broader market dynamics, drawing comparisons to prominent meme assets.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is gaining significant attention following its milestone ceremony to begin drilling work for the KRONOS microreactor, alongside securing a substantial, oversubscribed private placement. This progress, combined with government awards and a strong pipeline, reinforces its position in the rapidly expanding advanced nuclear sector, driven by the critical energy demands of AI data centers. Community discussions highlight NNE's potential amidst debates over Small Modular Reactor (SMR) viability, distinguishing it from peers with tangible developmental steps.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending after a cautious 2026 outlook, projecting flat to modest sales growth that fell short of analyst expectations and highlighted persistent headwinds from the housing market. The community is actively discussing the impact of high interest rates and cautious consumer spending on big-ticket home improvement projects, with many comparing its future prospects against competitors. While some view the current valuation as stretched given the no-growth forecast, others see the recent dip as a potential entry point for a long-term recovery.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW) is trending with its highly engaged community driving significant buzz through its signature "caw caw" rallying cry. The crypto is gaining traction due to its expanding multichain presence across platforms like Solana, Base, Cronos, and BSC, with many anticipating substantial growth. Community discussion also highlights collaborative and playful interactions with other meme tokens, notably $PMV.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>&nbsp;</li></ul>&nbsp;Shares of Altimmune, Inc. (ALT) jumped 16% in premarket trading on Friday after it reported positive topline results from its Phase 2b IMPACT trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).Pemvidutide is a drug that targets both GLP-1 and glucagon receptors and is used to treat liver diseases.The company said that the 48-week data showed statistically significant improvements versus placebo in key non-invasive liver tests, including enhanced liver fibrosis and liver stiffness, with continued progress from week 24. The higher dose also delivered additional weight loss without signs of plateauing, while maintaining a favorable safety profile.Altimmune said it held a productive End-of-Phase 2 meeting with the FDA, aligning on plans for a registrational Phase 3 trial."These results reinforce that pemvidutide may address both liver-specific and metabolic drivers of MASH without compromising tolerability – three critical elements of a potential effective treatment for this patient population,” said Mazen Noureddin, M.D., IMPACT trial principal investigator, Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board for Summit and Pinnacle Clinical Research.&nbsp;<a href="https://stocktwits.com/symbol/ALT">ALT</a> was the top-trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits shifted to 'bullish' from 'neutral' a day earlier.&nbsp;One user said proof that pemvidutide is an effective GLP1/Glucagon agonist continues to grow.<stembedurl>https://stocktwits.com/Independentquest/message/639732825</stembedurl>However, another user was bearish on the stock's price movement.<stembedurl>https://stocktwits.com/4Reel/message/639729717</stembedurl>Year-to-date, the stock has declined more than 40%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug

New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.

Why Is Altimmune Stock Up Over 10% Before The Bell?

Equity

Altimmune (NASDAQ:ALT) Stock Price Up 12.2% - Here's Why

Altimmune (NASDAQ:ALT) Stock Price Up 12.2% - Still a Buy...

Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?

The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT

Geode Capital Management LLC lifted its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 13.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission...

Altimmune (NASDAQ:ALT) Stock Price Down 6.6% - Time to Sell?

Altimmune (NASDAQ:ALT) Shares Down 6.6% - Here's What Happened...

Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT

Intech Investment Management LLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 102.9% during the second quarter, according to the company in its most recent Form 13F...

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat...

Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw some unusual options trading on Monday. Investors bought 11,978 call options on the company. This is an increase of 103% compared to the typical...

Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

<ul class="summary-bullets"><li>Retail traders focused on AI-driven biopsy findings and clearer dose-response&nbsp;exuded increased confidence in pemvidutide’s potential.</li><li>Analysts remained divided, with&nbsp;some citing strong MASH resolution and safety, while skeptics questioned differentiation and funding needs.</li><li>Lancet publication and AASLD late-breaker added momentum as Altimmune advanced additional liver-disease programs toward 2026 readouts.</li></ul>Retail discussion around Altimmune intensified over the weekend as investors looked ahead to the 48-week readout from the company’s IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2025.&nbsp;<h2 class="st-heading-2">AI-Based Biopsy Analysis Adds Fresh Momentum</h2>Last week, Altimmune released results from an AI-based analysis of liver biopsies from the IMPACT Phase 2b trial. The company reported that 31% of patients in the 1.8 mg pemvidutide arm and 12% in the 1.2 mg arm achieved a 60% reduction in total fibrosis, compared with 8% for placebo. Improvements were also observed in early and advanced fibrosis categories, with reductions in the area of fibrosis exceeding 60% in select patient groups compared with placebo.Following the analysis, Citizens JMP lowered its price target to $14 and maintained an ‘Outperform’ rating,&nbsp;noting that&nbsp;it looked ahead to the late-breaking oral presentation at the Liver Meeting and the 48-week dataset expected this quarter. UBS maintained a ‘Buy’ rating, while Jefferies reiterated its ‘Buy’ recommendation, viewing pemvidutide as viable after meeting key histology endpoints at 24 weeks.<h2 class="st-heading-2">Mixed MASH Readout In July Still Shapes Sentiment</h2>Altimmune’s June and July update on its 24-week IMPACT&nbsp;Phase 2b results set the tone for the stock this year.&nbsp;The company reported that up to 59.1% of patients on pemvidutide achieved MASH resolution without worsening of fibrosis, compared to 19.1% for the placebo group. However, the endpoint of fibrosis improvement without worsening of MASH did not reach statistical significance.Despite this, the trial showed reductions in liver fat, inflammation and biomarkers of fibrosis, alongside meaningful weight loss, with up to 6.2% loss in treated patients compared with 1.0% for placebo. Safety remained favorable, with extremely low discontinuations and no drug-related serious adverse events.<h2 class="st-heading-2">Analyst Community Diverges Across The Year</h2>Bullish analysts’ optimism hinged on the drug’s early MASH resolution signal, weight loss trajectory and tolerability. UBS, Stifel, Jefferies and H.C. Wainwright all maintained ‘Buy’ ratings at various points, describing the 24-week results as either differentiated, fast-acting, viable for Phase 3 advancement or supportive of a potential best-in-class profile. Several of these firms highlighted AI-assisted fibrosis reads and non-invasive tests as consistent with anti-fibrotic activity.Others expressed more skepticism. In October, Citizens JMP cut its target earlier, while still keeping an ‘Outperform’ rating. Goldman Sachs resumed coverage with a ‘Sell’ rating, citing a lack of meaningful differentiation in obesity and MASH. Concerns about the company’s ability to fund a full Phase 3 program, especially after the mixed fibrosis outcome, were noted among analysts.<h2 class="st-heading-2">Peer-Reviewed Boost</h2>Last week, Altimmune said that The Lancet had published the 24-week efficacy and safety data from the IMPACT Phase 2b trial. The data were also selected for a late-breaking oral presentation at The Liver Meeting 2025 hosted by AASLD. Investigators highlighted significant MASH resolution, reductions in liver fat, anti-fibrotic signals and weight loss, reinforcing the drug’s potential to treat patients with moderate to advanced fibrosis.<h2 class="st-heading-2">Stocktwits Users See No ‘Breaks’ Ahead</h2>On Stocktwits, retail sentiment for Altimmune was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/139;" src="https://news.stocktwits-cdn.com/alt_ss_jpg_da81507313.webp" alt="alt ss.jpg" width="972" height="139"><figcaption>ALT sentiment and message volume as of November 16 | Source: Stocktwits</figcaption></figure>One user discussing the upcoming 48-week dataset pointed to the latest AASLD-published fibrosis odds-ratio findings and the clearer dose-response signals seen in the PathAI-derived analysis, suggesting these results strengthen the case for exploring a higher 2.4 mg dose aimed at accelerating fibrosis reduction, while keeping 1.8 mg and 1.2 mg positioned for broader cardiometabolic use and long-term maintenance.<stembedurl>https://stocktwits.com/BTECHINV/message/636410473</stembedurl>Another user said, “If 48 week MASH data is ‘BEST IN CLASS’ like the weight loss/muscle sparring data, we should get at least $15B for both…not to mention the other indications.”<stembedurl>https://stocktwits.com/Lazarus2024/message/636408646</stembedurl>A third user said, “48 week should confirm fibrosis improvement and we should race to 2 billion MC on it FAST. no breaks once it’s out.”<stembedurl>https://stocktwits.com/SuperPuncher/message/636408207</stembedurl><a href="https://stocktwits.com/symbol/ALT">Altimmune’s stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALT News

ALTAltimmune Inc